Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized 2 x 2 Factorial Trial of Rabbit Anti-thymocyte Globulin Induction (Single vs. Alternate Day Administration) at Renal Transplantation, With Delayed Calcineurin-inhibitor Withdrawal vs. Minimization
Brief Summary: This 2 x 2 sequential factorial study evaluates two potential improvements to the standard immunosuppression regimen used at the investigators' institution to prevent rejection of transplanted kidneys. These two potential improvements are each applied in sequence to half of the study patients, creating 4 study arms; the other half receive the standard treatment. The two potential improvements are:

1. Administering the immunosuppression induction agent rATG ("rabbit anti-thymocyte globulin") in a single dose at the time of transplantation, instead of in the usual series of 4 smaller doses over 6 days.
2. After 6 months, modifying the maintenance immunosuppression used to prevent rejection by replacing the drug tacrolimus with mycophenolate mofetil (MMF).

The two interventions, spaced sequentially six months apart, enable independent analysis of the two treatments so long as it can be shown that there is no synergistic interaction between them.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - single dose, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - 4 doses, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - single dose, Drug: mycophenolate mofetil, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Drug: mycophenolate mofetil, Drug: rabbit anti-thymocyte globulin - 4 doses, Drug: sirolimus, Drug: tacrolimus | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin - single dose; Assigned to Arm(s): Group 1, Group 3 | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Group 3, Group 4 | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin - 4 doses; Assigned to Arm(s): Group 2, Group 4 | Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4 | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4
B: Arm Label: 1: Myfortic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate Sodium Delayed Release Tablets | Arm Label: 2. Cellcept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate Mofetil | Intervention Type: DRUG; Name: Mycophenolate Sodium Delayed Release Tablets; Assigned to Arm(s): 1: Myfortic | Intervention Type: DRUG; Name: Mycophenolate Mofetil; Assigned to Arm(s): 2. Cellcept
C: Arm Label: Single-dose Thymoglobulin; Type: EXPERIMENTAL; Interventions: Biological: Single-dose rabbit Anti-thymocyte Globulin induction | Arm Label: Divided-dose Thymoglobulin; Type: ACTIVE_COMPARATOR; Interventions: Biological: Divided-dose rabbit Anti-thymocyte Globulin induction | Intervention Type: BIOLOGICAL; Name: Single-dose rabbit Anti-thymocyte Globulin induction; Assigned to Arm(s): Single-dose Thymoglobulin | Intervention Type: BIOLOGICAL; Name: Divided-dose rabbit Anti-thymocyte Globulin induction; Assigned to Arm(s): Divided-dose Thymoglobulin
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Thymoglobulin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Campath-1H | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Daclizumab | Intervention Type: DRUG; Name: Thymoglobulin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Campath-1H; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): C

Answer: A